Oligometastatic Prostate Cancer
Conditions
Brief summary
A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis). The aim is to compare time to progression between the two study arms: SBRT only or SBRT and hormonotherapy (ADT). The primary objective is to compare the progression-free survival (PFS) defined as the absence of new metastatic lesions (local, regional or distant) between the two arms. The secondary endpoints include the comparison of overall survival (OS), biochemical progression-free survival (BPFS), ADT-free survival, local control, treatment-induced acute and late toxicity, time to castration-resistant disease and QoL between the two arms; the development of a dedicated biobanking (collection of plasma and serum) for further biological investigation of predictive/diagnostic factors for personalized treatment; the preliminary evaluation of prognostic biomarkers; the correlation between imaging-derived parameters and treatment outcome.
Interventions
DRUGAndrogen deprivation therapy (ADT)
SBRT + ADT
RADIATIONSBRT
SBRT to all radiological documented lesions (bone or lymphnodes)
Sponsors
European Institute of Oncology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven initial diagnosis of adenocarcinoma of the prostate; * Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed adjuvant/salvage radiotherapy) +/- ADT according to the European Association of Urology (EAU) guidelines 2016 \[18\] or after any salvage therapy if biochemical progression is diagnosed in the context of castration sensitive PCa; * Nodal relapse in the pelvis, extra-regional nodal relapse (M1a), bone metastases (M1b) on Ch-PET/CT or WBMRI with a maximum of 3 lesions; * Serum testosterone level \>50 ng/dl at the time of randomization (castration sensitive PCa) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1; * Age ≥18 years; * Written informed consent signed
Exclusion criteria
* Serious concomitant comorbidities or contraindication to SBRT and/or ADT; * Previous invasive cancer (within 3 years before the prostate cancer diagnosis) apart from non-melanoma skin malignancies; * No ability to complete questionnaires about QoL; * Presence of mental diseases that cannot ensure valid informed consent;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | up 3 months from the end of the treatment up to radiological progression within 3 years | Defined as the absence of new metastatic lesions (local, regional or distant) between the two arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | Up the end of SBRT until death for cancer or other causes up to 3 years | From the end of RT treatment to the time of clinical progression or mortality from specific disease cause |
| Biochemical progression-free survival (BPFS) | up 3 months from the end of the treatment up to 3 years | Biochemical progression is defined according to the EAU guidelines \[18\], namely a rising PSA level \>0.2 ng/ml following radical prostatectomy and \>2 ng/ml above the nadir after radiation therapy. |
| Numbers of patients who experienced acute and late toxicity | Up to 1 months after treatment completion and then up to 3 years | Toxicity will be assessed according to the Common Toxicity Criteria for adverse events (CTCAE) toxicity criteria v4.3 |
Countries
Italy
Contacts
Primary ContactBarbara A Jereczek-Fossa, Prof
Backup ContactGiulia marvaso, MD
Outcome results
None listed